NASDAQ:KRSA Cyclerion Therapeutics Q2 2025 Earnings Results & Report $33.92 +0.41 (+1.22%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$33.87 -0.05 (-0.15%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cyclerion Therapeutics reported Q2 2025 earnings on August 5, 2025. The company reported EPS of -$0.77. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 5, 2025TimeAfter Market Closes Cyclerion Therapeutics EPS ResultsActual EPS-$0.77Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACyclerion Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCyclerion Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Cyclerion Therapeutics Q2 2025 Earnings FAQ Did Cyclerion Therapeutics beat earnings estimates for Q2 2025? Cyclerion Therapeutics (NASDAQ:KRSA) reported earnings of -$0.77 per share for Q2 2025. The report was announced on Tuesday, August 5, 2025. When is Cyclerion Therapeutics' next earnings date? Cyclerion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cyclerion Therapeutics on the company's earnings history page. Cyclerion Therapeutics Earnings HeadlinesComparing Cyclerion Therapeutics (NASDAQ:CYCN) and Redhill Biopharma (NASDAQ:RDHL)October 8 at 4:59 AM | americanbankingnews.comCervoMed (NASDAQ:CRVO) versus Cyclerion Therapeutics (NASDAQ:CYCN) Head to Head AnalysisOctober 7 at 5:15 AM | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 10 at 1:00 AM | Porter & Company (Ad)Wedbush Begins Coverage on Cyclerion Therapeutics (NASDAQ:KRSA)October 5, 2026 | americanbankingnews.comCyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Average Target Price of $56.00October 3, 2026 | americanbankingnews.comCyclerion Therapeutics (NASDAQ:KRSA) Upgraded at Wall Street ZenOctober 3, 2026 | americanbankingnews.comSee More Cyclerion Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclerion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclerion Therapeutics and other key companies, straight to your email. Email Address About Cyclerion TherapeuticsCyclerion Therapeutics (NASDAQ:KRSA) was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function. Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease. The company was founded in 2019 as a spinout from Ironwood Pharmaceuticals and was headquartered in Cambridge, Massachusetts. Peter Hecht, Ph.D., served as its chief executive officer during a significant portion of its operations. Public information identifies Cyclerion’s historical Nasdaq trading symbol as CYCN rather than KRSA, and the company’s corporate status and operations may have changed since its period as an independent biotechnology business.View Cyclerion Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
